Mepolizumab for airway inflammation in COPD
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a medication called mepolizumab (given as an injection) in people with COPD who have high eosinophils and frequent flare-ups. The goal is to see if it reduces inflammation and helps them breathe better, by looking at airway changes with special scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 85 years old
- You have a type of COPD with high eosinophils (a certain white blood cell) seen in your blood tests
- You have COPD with frequent flare-ups — at least 2 moderate ones or 1 severe one (needing hospital care) in the last year
- You are a former smoker who quit at least a year ago, with a history of smoking 10 or more pack-years (that's about a pack a day for 10 years)
- You are currently on a combination of three inhaler types (often called 'triple therapy') for at least 3 months
- You have never been diagnosed with asthma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether mepolizumab can reduce ongoing or returning asthma flare-ups in people with severe asthma. If you have severe asthma that still keeps flaring, this may help by targeting a specific inflammation pathway involved in some asthma cases.
This trial tests how well mepolizumab works for people with asthma or a related condition called EGPA, and looks for markers in the blood that may predict organ damage or treatment response.
This trial tests a new biologic medicine called depemokimab, given as an injection, to see if it reduces flare-ups (exacerbations) in people with COPD who have a specific type of inflammation (high eosinophils). It may help if you have frequent flare-ups despite using your regular inhalers.
This study tests a new biologic medicine, given as an injection, to see if it can reduce flare-ups in adults with COPD who have a certain type of inflammation. It may help people who still have frequent exacerbations despite using their current inhalers.
This study looks at blood and other measures (biomarkers) to understand how well mepolizumab helps people with nasal polyps, with or without asthma. It aims to find response clues that could help personalize treatment in the future.
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.